B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin-Reference-Cited by-同舟云学术

B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin

Published:2019-06-19 Issue:10 Volume:26 Page:1200-1209
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Ridruejo Ezequiel¹²³^ORCID,Cheinquer Hugo³⁴,Marciano Sebastián⁵⁶,Mendizabal Manuel²³^ORCID,Piñero Federico²³,Wolff Fernando H.⁴,Araujo Alexandre⁴,Coelho Borges Silvia⁴,Kliemann Dimas⁴,Fleck Alfeu⁴,de Maman Ítalo⁴,Nader Lysandro A.⁴,Garrastazul Patricia²,Bermúdez Carla⁵,Haddad Leila⁵,Gadano Adrián⁵⁶,Silva Marcelo²³

Affiliation:

1. Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno ‘CEMIC’ Buenos Aires Argentina

2. Hepatology and Liver Transplant Unit Hospital Universitario Austral, Presidente Derqui Buenos Aires Argentina

3. Latin American Liver Research Educational and Awareness Network (LALREAN) Pilar Argentina

4. Gastroenterology and Hepatology Division Hospital de Clínicas de Porto Alegre Porto Alegre Brazil

5. Liver Unit Hospital Italiano de Buenos Aires Buenos Aires Argentina

6. Research Department Hospital Italiano de Buenos Aires Buenos Aires Argentina

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13148

Reference42 articles.

1. WHO.Global hepatitis report 2017. Available athttp://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1. Accessed on November 15 2018.

2. PAHO and WHO.OPS/OMS alienta a los países de las Américas a actuar para reducir muertes por hepatitis y mejorar la prevención y el tratamiento.2017. Available athttp://www.paho.org/hq/index.php?option=com_content&view=article&xml:id=12334%3Aopsoms-alienta-paises-americas-reducir-muertes-por-hepatitis&Itemxml:id=1926&xml:lang=es. Accessed on November 15 2018.

3. SOVALDI® (sofosbuvir) tablets for oral use. U.S. prescribing information. Available at:http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204671s001lbl.pdf. Accessed on November 15 2018.

4. SOVALDI® (sofosbuvir) tablets for oral use. European prescribing information. Available at:https://www.ema.europa.eu/documents/product-information/sovaldi-epar-product-information_en.pdf. Accessed on November 15 2018.

5. DAKLIZA® (daclatasvir) tablets for oral use. European prescribing information. Available at:https://www.ema.europa.eu/documents/overview/daklinza-epar-summary-public_en.pdf. Accessed on November 15 2018.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation;Expert Opinion on Pharmacotherapy;2022-11-17

2. Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2022-09-15

3. Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review;Hepatology International;2022-09-09

4. Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort;Medicine;2022-09-02

5. Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis;Journal of Clinical and Translational Hepatology;2022-06-28